This multi-project proposal describes several novel technologies directed at the development of a new form of epitope-based dengue genetic vaccine encoding an ensemble of selected antigen peptide units (epitopes) containing the minimum antibody and cellular antigen sequences required for an effective vaccine applicable to all serotypes (tetravalent) and to genetically diverse human populations, and lacking cytotoxic T-cell epitopes associated with hemorrhagic fever. The combination of epitope selection, targeting to the MHC II compartment, and ex vivo analysis of the immune responses with samples of a well-characterized patient cohort can be predicted to achieve a vaccine superior to those based on other strategies, and to be applicable to other pathogens. Bioinformatic computational analysis (Project 1) will be applied to identify epitope sequences selected for binding to clusters of major histocompatability class (MHC) motifs representing multiple human lymphocyte antigen (HLA) alleles (promiscuous epitopes) and effective with each of the four dengue serotypes (pan-dengue epitopes). This will include MHC II binding motifs for epitope presentation to CD4+ helper T-cells which play a critical role in the immune response system. MHC I binding motifs of CD8+ cytotoxic T-cell epitopes will also be examined both for their possible role in prevention of infection and proposed negative role in the etiology of dengue hemorrhagic fever. A human ex vivo T-cell activation assay will be used to analyze the biological correlates of the selected epitope candidates (Project 2). Analysis of human responses to epitopes is critical for vaccine development, particularly in the response to HLA-restricted T-cell epitopes. Peripheral blood samples will be obtained from a well-characterized cohort of dengue subjects (Core B). An ex vivo lymphocyte stimulation assay will identify those epitopes that stimulate the naturally induced T- and B-cells and are promiscuous to multiple HLA alleles. The results will be used to refine the bioinformatic models, for correlations to the severity of disease, and for vaccine construction. Selected epitopes will be tested initially as peptides and subsequently as nucleic acid encoded chimeric antigens (Project 4). A novel PCR assay will be used for differential diagnosis of dengue serotypes and other diseases (Project 3). The appropriate selection of patient blood samples requires rapid and accurate differential diagnosis of other diseases with similar symptoms (other flaviviruses, arenaviruses and huntaviruses). A novel multiplex format in a polymerase chain reaction (PCR) assay will provide rapid identification of viruses and additionally is designed for specific quantification of cellular replicating virus. This assay will be applied to patient selection for the Core B cohort. A tetravalent, pan-HLA, MHC II-targeted dengue DNA vaccine (Project 4) will incorporate the epitopes into an antigen chimera directed to the MHC II compartment for the required activation of CD4+ helper T-cells by targeting signals of the lysosome-associated membrane protein (LAMP) that is colocalized by MHC II and enhances all arms of the immune response CD4+, CD8+ and antibody. Epitope mapping technologies will be applied with both mouse and human antisera to identify the minimum sequences of the viral envelope proteins effective as neutralizing antibody epitopes. The vaccine constructs will be validated for human dengue virus specific T- and B-cell responses by the human ex vivo assay system (Project 2), and by mouse immunization for neutralizing antibody response (Project 4). Core A will provide central administration and financial management of the program and Core B, the peripheral blood samples of the dengue patient cohort. Additionally, the Cores will maintain a customized relational database system designed to support and streamline all aspects of the vaccine development process. As such, it will comprise integrated database """"""""modules"""""""" for the entry, searching, tracking, and analysis of process-critical data from the early collection of blood samples from cohort patients, through the preliminary assays, and culminating in the vaccine trials of the candidate dengue epitope-defined LAMP chimera.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI056541-03
Application #
6887342
Study Section
Special Emphasis Panel (ZAI1-ALR-M (M3))
Program Officer
Winter, David B
Project Start
2003-09-30
Project End
2008-03-31
Budget Start
2005-04-01
Budget End
2006-03-31
Support Year
3
Fiscal Year
2005
Total Cost
$1,424,623
Indirect Cost
Name
Johns Hopkins University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Khan, Asif M; Hu, Yongli; Miotto, Olivo et al. (2017) Analysis of viral diversity for vaccine target discovery. BMC Med Genomics 10:78
Oliveira, Renato Antônio Dos Santos; Silva, Mayara Marques Carneiro da; Calzavara-Silva, Carlos Eduardo et al. (2016) Primary dengue haemorrhagic fever in patients from northeast of Brazil is associated with high levels of interferon-? during acute phase. Mem Inst Oswaldo Cruz 111:378-84
Maciel Jr, Milton; Cruz, Fábia da Silva Pereira; Cordeiro, Marli Tenório et al. (2015) A DNA vaccine against yellow fever virus: development and evaluation. PLoS Negl Trop Dis 9:e0003693
Santos, Jefferson J S; Cordeiro, Marli T; Bertani, Giovani R et al. (2014) A two-plasmid strategy for engineering a dengue virus type 3 infectious clone from primary Brazilian isolate. An Acad Bras Cienc 86:1749-59
Santos, Jefferson J S; Cordeiro, Marli T; Bertani, Giovani R et al. (2014) A two-plasmid strategy for engineering a dengue virus type 3 infectious clone from primary Brazilian isolate. An Acad Bras Cienc 0:0
Comber, Joseph D; Karabudak, Aykan; Huang, Xiaofang et al. (2014) Dengue virus specific dual HLA binding T cell epitopes induce CD8+ T cell responses in seropositive individuals. Hum Vaccin Immunother 10:3531-43
Pastor, André F; Rodrigues Moura, Laís; Neto, José W D et al. (2013) Complement factor H gene (CFH) polymorphisms C-257T, G257A and haplotypes are associated with protection against severe dengue phenotype, possible related with high CFH expression. Hum Immunol 74:1225-30
Castanha, P M S; Cordeiro, M T; Martelli, C M T et al. (2013) Force of infection of dengue serotypes in a population-based study in the northeast of Brazil. Epidemiol Infect 141:1080-8
Carvalho-Leandro, D; Ayres, C F J; Guedes, D R D et al. (2012) Immune transcript variations among Aedes aegypti populations with distinct susceptibility to dengue virus serotype 2. Acta Trop 124:113-9
Rodriguez-Barraquer, Isabel; Cordeiro, Marli T; Braga, Cynthia et al. (2011) From re-emergence to hyperendemicity: the natural history of the dengue epidemic in Brazil. PLoS Negl Trop Dis 5:e935

Showing the most recent 10 out of 38 publications